Biome Australia Ltd (AU:BIO)
ASX:BIO
Want to see AU:BIO full AI Analyst Report?
Top Page
Biome Australia Ltd
(Sydney:BIO)
Select Model
Select Model
Rating:57Neutral
Price Target:
AU$0.35
▼(-12.00% Downside)
Action:ReiteratedDate:01/06/26
The score is driven primarily by decent financial progress (revenue growth and strong gross margin) and improving technical momentum. However, the overall rating is held back by cash flow weakness (negative operating cash flow) and a very stretched valuation (P/E 455).
Positive Factors
Focused product & distribution model
Biome's focused microbiome and probiotic product portfolio and established pharmacy/practitioner/wholesale routes create predictable reorder behavior and trusted clinical distribution. Durable channel relationships support recurring revenue, brand credibility and efficient route-to-market over months to years.
Negative Factors
Negative operating cash flow
Operating cash flow that is negative despite reported profits indicates earnings aren't converting to cash. This weak cash conversion constrains the company's ability to self-fund inventory, marketing and expansion, increasing reliance on external financing and raising execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused product & distribution model
Biome's focused microbiome and probiotic product portfolio and established pharmacy/practitioner/wholesale routes create predictable reorder behavior and trusted clinical distribution. Durable channel relationships support recurring revenue, brand credibility and efficient route-to-market over months to years.
Read all positive factors
Biome Australia Ltd (BIO) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$79.80M
Dividend YieldN/A
Average Volume (3M)278.69K
Price to Earnings (P/E)19.7
Beta (1Y)1.22
Revenue Growth41.57%
EPS GrowthN/A
CountryAU
Employees30
SectorConsumer Defensive
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)<0.01
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.12
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biome Australia Ltd Business Overview & Revenue Model
Company Description
Biome Australia Limited develops, commercializes, and markets various live biotherapeutics and complimentary medicines in Australia and internationally. It provides live biotherapeutic products under the Activated Probiotics brand; organic nutrace...
How the Company Makes Money
BIO makes money primarily by selling its microbiome and gut-health product portfolio (e.g., probiotic and related formulations) into Australian channels. Revenue is generated from product sales to, or through, (1) pharmacies and pharmacy groups, (...
Biome Australia Ltd Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
70
Positive
Cash Flow
50
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.95M | 18.42M | 13.01M | 7.24M | 4.11M | 2.32M |
| Gross Profit | 13.28M | 11.26M | 7.91M | 4.06M | 2.38M | 1.07M |
| EBITDA | 765.13K | 143.57K | -1.58M | -3.15M | -4.65M | -5.39M |
| Net Income | 957.91K | 214.66K | -1.67M | -3.08M | -4.54M | -5.38M |
Balance Sheet | ||||||
| Total Assets | 12.31M | 11.97M | 8.28M | 7.56M | 8.25M | 11.09M |
| Cash, Cash Equivalents and Short-Term Investments | 3.36M | 2.75M | 2.87M | 2.26M | 5.49M | 634.61K |
| Total Debt | 2.43M | 3.07M | 1.30M | 1.15M | 467.05K | 81.00K |
| Total Liabilities | 6.25M | 7.29M | 5.37M | 3.97M | 1.73M | 920.00K |
| Stockholders Equity | 6.06M | 4.68M | 2.90M | 3.59M | 6.53M | 10.17M |
Cash Flow | ||||||
| Free Cash Flow | 355.74K | -2.86M | -185.41K | -3.90M | -3.55M | -2.46M |
| Operating Cash Flow | 390.84K | -2.82M | -163.81K | -3.50M | -3.42M | -2.39M |
| Investing Cash Flow | -140.48K | -200.38K | -21.61K | -400.94K | -99.34K | -28.77K |
| Financing Cash Flow | 518.57K | 2.90M | 793.17K | 665.21K | 8.40M | 2.58M |
Biome Australia Ltd Technical Analysis
Negative
0.40
Price Trends
0.38
Negative
0.40
Negative
0.45
Negative
Market Momentum
>-0.01
Negative
43.20
Neutral
62.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BIO, the sentiment is Negative. The current price of 0.4 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.38, and below the 200-day MA of 0.45, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.20 is Neutral, neither overbought nor oversold. The STOCH value of 62.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:BIO.
Biome Australia Ltd Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
57 Neutral | AU$79.80M | 19.71 | 17.85% | ― | 41.57% | ― | |
53 Neutral | AU$33.06M | -6.66 | -370.40% | ― | 306.88% | ― | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
44 Neutral | AU$10.98M | -1.25 | -140.35% | ― | ― | ― | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 1.03% | |
40 Underperform | AU$2.17M | -5.50 | -32.19% | ― | ― | 46.43% |
* Consumer Defensive Sector Average
AU:BIO
Biome Australia Ltd
0.35
-0.10
-21.35%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
AU:BGT
Bio-Gene Technology Ltd.
0.04
0.01
56.00%
AU:HXL
Hexima Ltd
0.01
0.00
0.00%
Biome Australia Ltd Corporate Events
Biome Australia Appoints New External Auditor Ahead of 2026 AGM
Apr 10, 2026
Biome Australia Ltd, a specialist in evidence-based probiotics and complementary medicines, partners with global microbiome researchers to develop its Activated Probiotics range, which targets issues such as mood, sleep, bone health, iron malabsor...
Biome Australia Options Lapse Without Exercise, Leaving Share Count Unchanged
Apr 1, 2026
Biome Australia Ltd has reported changes to its capital structure following the expiry of a series of listed options. The company notified the market that 2.5 million BIOAQ options, exercisable at $0.50 and due to expire on 31 March 2026, have lap...
Biome Australia Clears Secondary Trading for 1 Million Newly Issued Shares
Mar 30, 2026
Biome Australia has issued 1,000,000 fully paid ordinary shares following the exercise of options, expanding its capital base and adjusting its share structure on the ASX. The company confirmed that these shares were issued without a prospectus bu...
Biome Australia Seeks ASX Quotation for 1 Million New Shares
Mar 30, 2026
Biome Australia Ltd has applied to the ASX for quotation of 1,000,000 new ordinary fully paid shares, with an issue date of 30 March 2026. The application, lodged as an Appendix 2A and marked as a new announcement, reflects the conversion or exerc...
Biome Australia Enables Trading of 2.5 Million New Shares After Option Exercises
Mar 19, 2026
Biome Australia Ltd has issued 2,513,802 fully paid ordinary shares following the exercise of options, expanding its share capital base. The company confirmed that these shares were issued without a prospectus but remain within the legal framework...
Biome Australia Seeks ASX Quotation for New Employee Incentive Shares
Mar 19, 2026
Biome Australia has applied to the ASX for quotation of 2,488,743 new ordinary fully paid shares, issued on 19 March 2026. The shares were issued under an employee incentive scheme and will be quoted on the market, indicating ongoing use of equity...
Biome Australia Seeks ASX Quotation for Additional Ordinary Shares
Mar 19, 2026
Biome Australia Ltd has applied to the ASX for quotation of an additional tranche of its ordinary fully paid shares, designated under ticker BIO. The application covers 25,059 new securities issued on 19 March 2026, modestly increasing the company...
Biome Australia Plans Targeted Share Placement on ASX
Mar 18, 2026
Biome Australia Ltd has notified the ASX of a proposed issue of up to 25,059 fully paid ordinary shares under a placement or similar type of capital raising. The shares, carrying the ASX code BIO, are scheduled for issue and quotation application ...
Biome Australia Clears 875,000 New Shares for Secondary Trading After Option Exercise
Mar 17, 2026
Biome Australia has issued 875,000 fully paid ordinary shares following the exercise of options, modestly increasing its share base and providing additional equity capital from existing option holders. The company confirmed it has met all relevant...
Biome Australia Seeks ASX Quotation for 875,000 New Shares
Mar 17, 2026
Biome Australia Ltd, listed on the ASX under the ticker BIO, has lodged an application with the exchange for quotation of additional ordinary fully paid shares. The filing does not outline the company’s underlying business operations or mark...
Biome Australia Director Blair Norfolk Increases Direct Shareholding
Mar 12, 2026
Biome Australia director Blair Vega Norfolk has increased his direct holding in the company through an on-market purchase of 40,000 fully paid ordinary shares on 12 March 2026. The transaction lifted his direct stake to 367,317 shares, while his i...
Biome Australia Clears Secondary Trading for 1 Million New Shares
Mar 12, 2026
Biome Australia Ltd has issued 1,000,000 fully paid ordinary shares upon the exercise of options, expanding its share capital without providing a prospectus-level disclosure to new investors. The company confirmed it remains compliant with its fin...
Biome Australia seeks ASX quotation for 1 million new shares
Mar 12, 2026
Biome Australia Ltd has applied to the ASX for quotation of 1,000,000 new fully paid ordinary shares under its ticker BIO. The securities, issued on 12 March 2026 following the exercise or conversion of existing options or other convertible securi...
Biome Australia outlines March 2026 expiry of unlisted options and potential $1.78m capital inflow
Mar 9, 2026
Biome Australia Limited is an Australian-based developer and marketer of evidence-based live biotherapeutics and complementary medicines, best known for its Activated Probiotics range. The company collaborates with leading microbiome research orga...
Biome Australia Posts Record Half-Year Revenue and Profit as Probiotics Brand Leads Pharmacy Growth
Feb 24, 2026
Biome Australia has reported record results for the first half of fiscal 2026, highlighting strong operational momentum and market traction for its ACTIVATED PROBIOTICS range. The company posted H1 revenue of $12.4 million, including $6.45 million...
Biome Australia lifts profit 172% on surging probiotic sales and stronger cash flow
Feb 22, 2026
Biome Australia reported a strong first half to 31 December 2025, with revenue up 39.9% to $12.40 million, driven by growth in its Activated Probiotics and Activated Therapeutics ranges across pharmacy and practitioner channels. Net profit after t...
Biome Australia Secures Ethics Approval for First Human Trial of Proprietary Probiotic BMB18
Feb 2, 2026
Biome Australia has received ethics approval from La Trobe University’s Human Research Ethics Committee to commence its first human clinical trial of its proprietary probiotic strain Lactobacillus plantarum BMB18 in February 2026. The 12R...
Biome Australia Delivers Record Quarter With Strong Revenue Growth and Cash Generation
Jan 26, 2026
Biome Australia reported its strongest quarter on record for the three months to 31 December 2025, with sales revenue of $6.5 million, up 41% on the prior corresponding period, and rolling 12‑month revenue of about $22 million. The company d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.